

Long-term outcome after mitral valve repair: a risk factor analysis

Marie-Antoinette Rey Meyer, Ludwig K. von Segesser, Michel Hurni,
Frank Stumpe, Karam Eisa, Patrick Ruchat*

Department of Cardiovascular Surgery, University Hospital, Lausanne, Switzerland

Received 4 December 2006; received in revised form 26 April 2007; accepted 14 May 2007; Available online 11 June 2007

Abstract

Objective: Mitral valve repair is the gold standard to restore mitral valve function and is now known to have good long-term outcome. In order to help perioperative decision making, we analyzed our collective to find independent risk factors affecting their outcome. **Methods:** We retrospectively studied our first 175 consecutive adult patients (mean age: 64 ± 10.4 years; 113 males) who underwent primary mitral valve repair associated with any other cardiac procedures between January 1986 and December 1998. Risk factors influencing reoperations and late survival were plotted in a uni- and multivariate analyses. **Results:** Operative mortality was 3.4% (6 deaths, 0–22nd postoperative day (POD)). Late mortality was 9.1% (16 deaths, 3rd–125th POM). Reoperation was required in five patients. Kaplan–Meier actuarial analysis demonstrated a $96 \pm 1\%$ 1-year survival, $88 \pm 3\%$ 5-year survival and a $69 \pm 8\%$ 10-year survival. Freedom from reoperations was 99% at 1 year after repair, $97 \pm 2\%$ after 5 years and $88 \pm 6\%$ after 10 years. Multivariate analysis demonstrated that residual NYHA class III and IV ($p = 0.001$, RR 4.55, 95% CI: 1.85–14.29), poor preoperative ejection fraction ($p = 0.013$, RR 1.09, 95% CI: 1.02–1.18), functional MR ($p = 0.018$, RR 4.17, 95% CI: 1.32–16.67), and ischemic MR ($p = 0.049$, RR 3.13, 95% CI: 1.01–10.0) were all independent predictors of late death. Persistent mitral regurgitation at seventh POD ($p = 0.005$, RR 4.55, 95% CI: 1.56–20.0), age below 60 ($p = 0.012$, RR 8.7, 95% CI: 2.44–37.8), and absence of prosthetic ring ($p = 0.034$, RR 4.76, 95% CI: 1.79–33.3) were all independent risk factors for reoperation. **Conclusions:** Mitral valve repair provides excellent survival. However, long-term outcome can be negatively influenced by perioperative risk factors. Risk of reoperation is higher in younger patients with a residual mitral regurgitation and without ring annuloplasty.

© 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Keywords: Mitral regurgitation; Mitral valve repair; Risk factors; Reoperation; Univariate and multivariate analysis

1. Introduction

The concept of correcting mitral regurgitation by elimination of the leaking site was introduced by Merendino et al. [1] in 1959 with their technique of posteromedial annuloplasty. In 1969, Carpentier [2] proposed a standardized technique of mitral repair which, as a key-principle, decreases the strain on still diseased subvalvular apparatus. Large number of studies showed that repair of degenerative mitral valve regurgitation offers a reduced operative mortality and a better event-free survival when compared to mitral valve replacement [3]. This has led to an increased use of techniques of repair over replacement in many settings like rheumatic, infectious, and ischemic mitral valve disease [4–6]. The 20-year Kaplan–Meier survival rate after repair of degenerative mitral valve regurgitation was 48% (95% CI: 40–57%), which is similar to the survival rate for a normal population with the same age structure [5]. Ten-year survival

freedom from redo mitral valve surgery varies from 72% to 90%. Risk factors influencing the early and late outcomes of patients with mitral valve regurgitation should be assessed to help perioperative decision making for optimal management. Excellent long-term outcome is already described by expert hands, but few data exist to define prognostic parameters valuable during the perioperative period for long-term results. Apart from surgical expertise, patient selection and correct indication for mitral valve repair (MVR) may significantly influence the long-term results. In this regard, we planned the present study to identify those variables which in our experience were associated with an increased risk of adverse long-term outcome.

2. Patients and methods

2.1. Patients' characteristics

This series included the first 175 consecutive patients (mean age: 64 years) who underwent MVR in our institution from January 1986 to December 1998. Any MVR done as a lone procedure or associated with any other cardiac procedures was

* Corresponding author. Address: Service de Chirurgie Cardio-Vasculaire, Centre Hospitalier Universitaire Vaudois, rue du Bugnon 46, CH-1011 Lausanne, Switzerland. Tel.: +41 21 314 2921; fax: +41 21 314 2278.

E-mail address: Patrick.Ruchat@chuv.ch (P. Ruchat).

included in this study. Data on pre-, intra- and postoperative variables were collected retrospectively from our database and patients' records by a single investigator (MAR). Demographic and operative data are summarized in Table 1.

2.2. Surgical procedures

Operations were performed through median sternotomy, aorto-bicaval cannulation, and the standard technique of cardiopulmonary bypass with moderate hypothermia (30–32 °C). Myocardial protection was obtained with antegrade intermittent crystalloid or cold blood cardioplegia combined with topical cooling. Intraoperative transesophageal echocardiography was carried out routinely before and after repair since January 1, 1992.

Mitral valve was exposed through standard left atriotomy. Valve analysis after Carpentier's functional classification showed normal leaflet motion (type I) in 37 patients (21%). A majority of patients ($n = 131$, 75%) had posterior leaflet prolapse with rupture of one or more chordae (type II). Finally, restricted leaflet motion (type III) was diagnosed in seven patients (4%). Repair technique was basically standardized with quadrangular resection of prolapsing posterior leaflet and annulus plication with 3–0 Prolen suture without sliding plasty; annuloplasty was carried on with Carpentier–Edwards ring. An annulovalvuloplasty was performed in 122 (70%) patients, an annuloplasty alone in 35 (20%) patients, and valvuloplasty without a prosthetic ring

in 18 (10%) patients because posterior annulus was found nondilated during routine valve inspection. In 57 patients (32%), another cardiac procedure was associated to MVR, 30 (17%) had coronary arterial bypass graft (CABG), 23 (13%) had a complementary valvular procedure, and 4 (2%) had both CABG and a valvular operation. In the immediate postoperative period, all patients were anticoagulated with moderate IV heparin dosage followed by oral anticoagulation with acenocoumarol (Novartis, Basel, Switzerland) for 3 months, unless patients had another prosthetic valve or chronic atrial fibrillation which indicated anticoagulation indefinitely. Operative events were defined as those occurring within 30 days after surgery or longer if it was during the same hospitalization. Quality of the repair was considered successful when the early transthoracic echocardiography showed only a trivial residual mitral valve incompetence (MVI) of 0–1/4, acceptable when the echo score was 2/4, and failed when the score was 3–4/4.

2.3. Follow-up

Data on long-term outcome were obtained by questionnaires addressed one-time to the physician in charge of the patients (response rate 82%) and by phone interview with all living patients and family or neighbors in case of death. Further information about complications was obtained from hospital reports and death certificates from the Swiss Federal Office of Civil Status. In the end, 8 among 175 patients were definitively lost. Follow-up was thus 95.4% complete and represented 728 patients-years with a mean of 8.7 years and a range from 2.3 to 18.1 years.

We used the published guidelines for reporting valve-related morbidity and mortality after cardiac valvular operation of the STS/AATS [7]. Adverse valvular events reported were all clearly cardiac, sudden death, or reoperations due to valve-related complications.

2.4. Statistical analysis

Data analysis was done on an intention-to-treat basis and was performed using a JMP statistical software package (JMP v. 5.1) from the SAS Institute Inc. (Cary, NC 27513, USA) on a Macintosh computer. Continuous variables were provided as mean \pm SD and compared with Student's *t*-test for parametric and Wilcoxon for nonparametric variables. Categorical data were analyzed univariately by χ^2 -test or Fischer's exact test. Actuarial survival and freedom from reoperation were calculated by the Kaplan–Meier method and were univariately compared using the log-rank statistic. To identify significant independent risk factors influencing late mortality, all factors with a significance less than 0.1 were entered into multivariate analysis. Risk ratio and 95% confidence intervals were calculated using a Cox proportional hazards model. A *p*-value of less than 0.05 was then considered statistically significant.

3. Results

Using the classical Kaplan–Meier approach, freedom from combined early and late deaths and reoperations were

Table 1
Preoperative and operative patients data

Age (mean age \pm SD)	64.0 \pm 10.4 (range 33–82 years)
Gender	
Male	113 (65%)
Female	62 (35%)
NYHA class	
I	16 (9%)
II	22 (13%)
III	86 (49%)
IV	51 (29%)
MR grading	
II	14 (7.5%)
III	43 (25%)
IV	118 (67.5%)
Cardiac rhythm	
Sinus rhythm	123 (71%)
Atrial fibrillation	48 (27%)
Pace maker	2 (1%)
Junctional	2 (1%)
Etiology	
Degenerative (myxomatous)	125 (71%)
Functional	16 (9%)
Ischemic	15 (9%)
Post-rheumatic	14 (8%)
Infectious endocarditis	5 (3%)
Types of operation	
Annulovalvuloplasty	122 (70%)
Isolated annuloplasty	35 (20%)
Isolated valvuloplasty	18 (10%)
Associated operations	
CABG	30 (17%)
Valve	23 (13%)
CABG and valve	4 (2%)




Fig. 1. Event-free survival. Survival freedom from reoperation and all cardiac events.

96 ± 1% at 1-year survival, 86 ± 3% at 5-year survival, and 61 ± 8% at 10-year survival (Fig. 1).

3.1. Early mortality

Six patients (3.4%) died perioperatively from OR time to 22nd postoperative day (POD). Two deaths were due to severe cardiogenic shock, one of severe intractable hemorrhage, one from a non-diagnosed late tamponade, one massive lung embolism in a Jehovah’s Witness, and one with multiple organ failure secondary to *Pseudomonas aeruginosa* pneumonia. Multivariate analysis showed that ischemic MR and NYHA IV functional status were independent risk factors for early mortality.

3.2. Late mortality

The overall mortality was 12.6% (22/175). Six patients had died perioperatively which left 169 patients for long-term follow-up. There were 16 late deaths (9.1%). Kaplan–Meier actuarial analysis showed a 96 ± 1% 1-year survival, 88 ± 3% 5-year survival and a 69 ± 8% 10-year survival. Most patients who died were in NYHA class III and IV and 75% were cardiac-related deaths with eight terminal ischemic cardiopathies, two sudden deaths, and two cardiac failures (Fig. 2).

Univariate analysis (Table 2) demonstrated that age older than 60 years, residual congestive heart failure, ischemic etiology, lone annuloplasty procedure, valvular-associated operations, residual MR, longer aortic clamping time, and




Fig. 2. Actuarial global survival. Survival freedom from early and late deaths.

Table 2
Late deaths univariate analysis

Late deaths	10 years survival	Deaths	p-value
Preoperative variables			
Age	63.2 ± 10.6 years	70.8 ± 6.7 years	0.006
LVEF	63 ± 12%	58 ± 14%	0.145
Size LA	53 ± 7 mm	53 ± 10 mm	0.972
BMI	24.1 ± 3.27	24.81 ± 3.76	0.413
Body area	17.76 ± 0.18	1.75 ± 0.16	0.841
Older than 60	60 ± 11%		0.034
Younger than 60	94 ± 4%		
Male	77 ± 9%		0.405
Female	61 ± 16%		
NYHA class III-IV	75 ± 17%		0.67
Others NYHA class	88 ± 7%		
Preoperative AF	64 ± 13%		0.721
No preoperative AF	80 ± 6%		
Etiology			
Degenerative valve disease	85 ± 7%		0.001
Others	38 ± 18%		
Ischemic	71 ± 18%		0.08
No ischemic	77 ± 7%		
Functional	52 ± 16%		0.001
No functional	75 ± 8%		
Rheumatic	58 ± 25%		0.557
No rheumatic	72 ± 9%		
Perioperative variables			
CEC timing	97.5 ± 30.6	138.0 ± 48.4	< 0.001
Aortic clamping time	68.2 ± 20.6	94.2 ± 33.5	< 0.001
Operation types			
Annulovulvoplasty	80 ± 8%		< 0.001
Others	44 ± 19%		
Annuloplasty	45 ± 20%		0.003
Others	79 ± 8%		
Valvuloplasty	67 ± 27%		0.488
Others	72 ± 8%		
Associated operations			
CABG	33 ± 25%		0.393
Others	77 ± 7%		
Associated valve	47 ± 16%		< 0.001
Others	75 ± 9%		
Postoperative variables			
Postoperative AF	69 ± 16%		0.891
No PO AF	72 ± 9%		
7 POD mitral insufficiency	74 ± 11%		0.072
No 7 POD MI	73 ± 8%		
NYHA class II–IV residual	39 ± 20%		< 0.0001
Others	96 ± 2%		

LVEF: left ventricular ejection fraction; LA: left atrium; BMI: body mass index; AF: atrial fibrillation; CABG: coronary arterial bypass graft; 7 POD: seventh postoperative day.

Bold = All parameters with $p \leq 0.05$.

longer CPB duration were significantly related to lower survival rates. Annulovulvoplasty and degenerative valve disease were associated with higher survival.

By multivariate analysis, the independent predictors of decreased long-term survival were residual NYHA class III and IV, ischemic MR, functional MR and preoperative ejection

fraction. Independent factors of late deaths are listed in Table 4.

3.3. Predictive factors of reoperation

Freedom from reoperation was 99% at 1 year, $97 \pm 2\%$ at 5 years and $88 \pm 6\%$ at 10 years. The annual linearized rate of valve failure is increasing progressively with postoperative years going by from 0.8% patient-year to 1.6%

patient-year. There were four valve-related reoperations from 2 to 95 postoperative months and one heart transplant for terminal dilated cardiomyopathy with progressive residual valve regurgitation 24 months after initial mitral valve repair. The two earliest operations (second and third POM) were due to technical failure with leaflet tear and annular suture leakage. The two latest (52nd and 95th POM) had posterior leaflet rupture and progressive posterior annulus dilatation due to absence of

Table 3
Reoperation univariate analysis

Reoperations	No reoperation in 10 years	Reoperation	p-value
Preoperative variables			
Age	64.4 \pm 10.4 years	51.4 \pm 4.3 years	0.006
LVEF	63 \pm 13%	61 \pm 8%	0.684
LA Size	53 \pm 8 mm	57 \pm 4 mm	0.074
BMI	24.1 \pm 3.2	25.2 \pm 2.3	0.426
Body surface area	1.75 \pm 0.18	1.91 \pm 0.15	0.046
Older than 60	100 \pm 0%		0.006
Younger than 60	72 \pm 13%		
Male	90 \pm 9%		0.101
Female	100 \pm 0%		
NYHA class III–IV	96 \pm 3%		0.233
Others NYHA class	93 \pm 4%		
Preoperative AF	92 \pm 8%		0.44
No preoperative AF	85 \pm 10%		
Etiology			
Degenerative valve disease	85 \pm 7%		0.207
Others	100 \pm 0%		
Ischemic	n.a		
No ischemic	n.a		
Functional	n.a		
No functional	n.a		
Rheumatic	100 \pm 0%		0.489
No rheumatic	87 \pm 7%		
Perioperative variables			
CEC timing (min)	101.4 \pm 35.5	99.6 \pm 13.4	0.908
Aortic clamping time	70.9 \pm 23.7	61.2 \pm 10.5	0.363
Operation types			
Annulovulvoplasty	96 \pm 4%		0.034
Others	88 \pm 7%		
Annuloplasty	94 \pm 5%		0.983
Others	87 \pm 7%		
Valvuloplasty	83 \pm 15%		0.005
Others	89 \pm 6%		
Associated operations			
CABG	96 \pm 4%		0.835
No CABG	87 \pm 7%		
Valve	100 \pm 0%		0.455
No valve	87 \pm 7%		
Postoperative variables			
7 POD mitral insufficiency	42 \pm 30%		0.0002
Others	93 \pm 6%		
Postoperative AF	97 \pm 3%		0.576
No postoperative AF	84 \pm 9%		

LVEF: left ventricular ejection fraction; LA: left atrium; BMI: body mass index; AF: atrial fibrillation; CABG: coronary arterial bypass graft; 7 POD: seventh postoperative day; n.a: not applicable.

Table 4
Independent risk factors of late death and reoperation at multivariate analysis

Multivariate analysis	p-value	Risk ratio	95% confidence interval
Late deaths			
Residual NYHA	0.001	4.55	1.85–14.29
Preoperative EF	0.013	1.09	1.02–1.18
Etiology functional	0.018	4.17	1.32–16.67
Etiology ischemic	0.049	3.13	1.01–10.0
Reoperations			
7 POD residual MR	0.005	4.55	1.56–20.0
Age <60 years	0.012	8.7	2.44–37.8
Valvuloplasty (absence of ring)	0.034	4.76	1.79–33.3

EF: ejection fraction; 7 POD MR: seventh postoperative day mitral regurgitation.

prosthetic ring implantation. All were degenerative mitral regurgitation.

Significant factors for reoperation risks are summarized in Table 3.

By multivariate analysis, the independent predictors of higher reoperation risks were patients younger than 60-year-old, the absence of prosthetic ring and the presence of a 7-day postoperative mitral insufficiency higher than degree I. (Table 4).

4. Discussion

4.1. Long-term outcome

Since the introduction of standardized techniques for mitral valve reconstruction by Carpentier, Duran and coworkers [8], mitral valve repair has become the surgical treatment of choice for mitral regurgitation. Independent predictors of mortality after any mitral procedures like ageing, NYHA IV functional class, female sex, diabetes, coronary artery disease, prior transient ischemic attack, and renal impairment have been already described [9]. Our short- and long-term survival results were similar to those obtained in a recent study [10] with 10-year survival of $68 \pm 2\%$. Our overall mortality was 12.5% in mitral valve repair for any etiologies; this is quite similar to the results found in literature varying between 4.5% in Italy and 18% in Alabama [11,12].

The main finding of this study is the identification of perioperative factors associated with a suboptimal long-term outcome, which help perioperative decision making to improve management in complicated settings. The etiology of MR plays a major role. We have shown that degenerative MR is a factor influencing positively late outcome, while ischemic (IMR) and functional mitral regurgitation (FMR) both act negatively on long-term prognosis. Ischemic mitral regurgitation is the second most common cause for mitral surgery in Western countries with a strong impact on late survival. In our cases, repair was performed because of annular dilation, while in patients with altered leaflet motion the valve had been replaced. IMR remains the subject of much debate and important insights have been gained only recently in the underlying pathophysiological mechanisms of the condition. It has been proved that annular dilation is only

one of the causes of IMR, while leaflet tethering, papillary muscle displacement, and ventricular remodeling play major roles. In a study comparing repair versus replacement, late mortality was not statistically different with an overall survival probability of $67 \pm 7\%$ at 5 years after repair versus $73 \pm 9\%$ after replacement [6]. In fact, in IMR, the long-term survival is dependent on preoperative left ventricular conditions and underlying pathophysiologic mechanisms like preoperative ejection fraction and preoperative pulmonary hypertension, rather than the choice of operative procedure [13]. It is noticeable that revascularization alone does not eliminate the negative long-term effects of even mild IMR [14].

Functional mitral regurgitation, defined as the failure of the mitral valve to prevent systolic backward flow in the absence of significant structural or intrinsic valvular disease, has been associated in 11 (48%) out of 23 patients with aortic valve replacement for aortic stenosis. Few papers deal with this problem. Ruel et al. [15] showed that significant FMR (>2+), increased aged, decreased ventricular function, and atrial fibrillation all had independent adverse effects on mortality. This demonstration pleads for a major part of increased risk of mortality found in our study with FMR.

Our study also confirms that despite preservation of the mitral apparatus, left ventricular dysfunction remains a major cause of poor short-term evolution for older patient suffering from bad cardiac function represented by low LVEF or residual functional class III and IV, and lower late survival by old patient with associated valvular operation or coronaropathy [16].

4.2. Reoperation

In patients with degenerative mitral valve disease, valve repair using Carpentier's technique is the gold standard for surgical correction of mitral regurgitation and has provided excellent long-term results. Braunberger et al. [5] recently reported the very long-term results of valve repair in non-rheumatic mitral valve insufficiency. In patients with isolated posterior leaflet prolapse, 10- and 20-year freedom from reoperation was 98.5% and 96.9%, respectively. In those with isolated anterior prolapse, it was 86.2% and 86.2%, respectively. Finally, in bileaflet prolapse, it was 88.1% and 82.6%, respectively. These data confirm the excellent results of Carpentier's standard techniques of repair and their stability over a long period of time. As this study reflects the beginning of our experience, most repair was done in isolated posterior prolapse and chordal rupture. Our good results are comparable with those of Perier et al. [17]. Although repair durability is good in these patients, some will require late reoperation for recurrent mitral valve dysfunction. Causes of failed mitral valve repair may be classified as procedure-related (suture dehiscence, incomplete initial operation, rupture of previously shortened chordae) or valve-related (progressive disease, endocarditis). Numerous studies have documented a high proportion of procedure-related repair failure and few like Flameng et al. [18] reported on valve-related linearized rate of failure. These authors showed that only 50% of patients remain free from more than trivial mitral incompetence at 7 years after repair. Their linearized recurrence rate of regurgitation >1/4 of 6.9% per year and

of regurgitation $>2/4$ of 2.5% per year were comparable with our rate of recurrence $>2/4$ of 1.6% per year. These findings strongly suggest a progression of the degenerative process with time. This is not surprising because myxoid changes are not entirely acquired but also genetically determined. Pathophysiological findings like glycosaminoglycans content of valve cells may help to explain why a progressive incidence of MR is found after initial adequate repair [19].

Residual regurgitation at intraoperative echocardiography has been identified by Mohty et al. [10] as an important factor associated with significantly increased risk of reoperation. In the present study, we found that residual regurgitation larger than grade 1/4 at routine postoperative TTE, absence of prosthetic ring insertion during the procedure and age younger than 60 years old were all independent predictors of late redo mitral valve surgery. Albeit, all patients who needed a reoperation had a degenerative etiology, this factor was not an independent predictor in our multivariate analysis. In the beginning of our experiment we did not check repair with perioperative ETO, and only failure were given in postoperative echocardiographic investigations. Since 1992, routine use of perioperative ETO helped the surgeon to select patients for mitral valve repair and gave immediate checking for quality of repair. Anterior leaflet prolapse was recognized in Carpentier series as an independent risk for reoperation. As this study reflects our early experience in MVR, operators were very cautious in selecting patients for valve repair. We used the somewhat pragmatic definition by Fasol and Mahdjoobian [20] which is based on gross appearance of the valve. Though we made an attempt to define the different forms of degenerative valve disease, mainly Barlow disease and fibroelastic deficiency. As we performed repair only if degenerative process involved less than 50% of leaflets (50% rule of thumb), we had only anecdotal anterior leaflets repair avoiding statistical analysis of this subgroup.

Gerbode' valvuloplasty without annulus reinforcement by a prosthetic ring is also a marker of reoperation. Our choice was given to the Carpentier ring, but tight anchorage of any type of annulus reinforcement prevented a high rate of mitral regurgitation progression and subsequent need for reoperation as described in a recent German study [21].

In our collective, all reoperated patients suffered from degenerative mitral regurgitation, all had trivial to acceptable residual MR at 7 days postoperative echocardiographic control, and all were younger than 60 years at first operation time.

Even if to our knowledge no reoperated patient had Marfan syndrome or trait of fibro-elastic deficiency, we can not exclude, due to the statistically higher reoperation rate by younger patients seen in our multivariate analysis, that a hereditary disease predisposed them to progression of the regurgitation after surgery because of the bad 'quality' of their tissues [22].

4.3. Limitation of the study

The major limitation of the present study is that most information was collected retrospectively, a process that may reduce the validity of some data. However, particular

attention was paid to the methods used in the follow-up by thorough examination of hospital files and precisising questionnaires with a doubled interview with physicians. Special emphasis was brought to define accurately the cause of late death, because most of the deceased patients had no necropsy [23]. Statistical power, when analysing covariates in certain subgroups such as endocarditis, was low because of small numbers of patients and events. Furthermore, the findings of this study, as with any observational cohort, may not necessarily be generalizable to all patients with mitral valve repair.

5. Conclusion

Perioperative management of patients undergoing mitral valve repair could be enhanced by accumulation of specific knowledge. Mitral valve repair has many advantages and improves the outcome of surgery for mitral regurgitation. However, older age, ischemic and functional origin of MR, supplementary valvular operation, and bad ventricular function (NYHA IV or low EF) were found to be independent risk factors of worse evolution for those patients. Reoperations rates were influenced badly by younger age at operation, persistent significative mitral regurgitation ($\geq 2+$), and the absence of prosthetic ring implantation.

References

- [1] Merendino K, Thomas G, Jesseph J. The open correction of rheumatic mitral regurgitation and/or stenosis with special reference to regurgitation treated by posteromedial annuloplasty utilizing a pump-oxygenator. *Ann Surg* 1959;150:5–22.
- [2] Carpentier A. A new technique of reconstructive mitral valvuloplasty. *Presse Med* 1969;77:251–3.
- [3] Enriquez-Sarano M, Schaff HV, Orszulack TA, Tajik AJ, Bailey KR, Frye RL. Valve repair improves outcome of surgery for mitral regurgitation. A multivariate analysis. *Circulation* 1995;91:1022–8.
- [4] Chauvaud S, Fuzellier JF, Berrebi A, Deloche A, Fabiani JN, Carpentier A. Long term (29 years) results of reconstructive surgery in rheumatic mitral valve insufficiency. *Circulation* 2001;104(Suppl. 1):I.12–5.
- [5] Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P, Chatellier G, Chauvaud S, Fabiani JN, Carpentier A. Very long-term results (more than 20 years) of repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. *Circulation* 2001;104(Suppl. 1):I.8–11.
- [6] Mantovani V, Mariscalco G, Leva C, Blanzola C, Cattaneo P, Sala A. Long-term results of the surgical treatment of chronic ischemic mitral regurgitation: comparison of repair and prosthetic replacement. *J Heart Valve Dis* 2004;13:421–9.
- [7] Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. *Eur J Cardiothorac Surg* 1996;10:812–6.
- [8] Pomar JL, Ubago JL, Colman T, Figueroa A, Revuelta JM, Duran CMG. Analysis of the results of 212 flexible annuloplasties in mitral position. *Rev Esp Cardiol* 1980;33:227–33.
- [9] Edwards RN, Birkmeyer NJO, Weintraub RW, Leavitt BJ, Sanders JH, Dacey LJ, Clough LA, O'Connor GT. Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in northern New England. *Ann Thorac Surg* 2004;77:1966–77.
- [10] Mohty D, Orszulack TA, Schaff HV, Avierinos JF, Tajif JA, Enriquez-Sarano M. Very long-term survival and durability of mitral valve repair for mitral valve prolapse. *Circulation* 2001;104(Suppl. 1):I.1–7.
- [11] Gramaglia B, Imazio M, Checco L, Villani M, Morea M, Di Summa M, Bonamini R, Rosettani E, Mangiardi L. Comparison between valvular repair and replacement in severe mitral regurgitation. *J Cardiovasc Surg* 1999;40:93–9.

- [12] Knott HW. Clinical study of mitral valve repair: short and long term outcomes. *South Med J* 1999;92:33–40.
- [13] Glower DD, Tuttle RH, Shaw LK, Orozco RE, Rankins JS. Patient survival characteristics after routine mitral valve repair for ischemic mitral regurgitation. *J Thorac Cardiovasc Surg* 2005;129:860–8.
- [14] Schroder JN, Williams ML, Hata JA, Muhlbaier LH, Swaminathan M, Mathew JP, Glower DD, O'Connor CM, Smith PK, Milano CA. Impact of mitral valve regurgitation evaluated by intraoperative transesophageal echocardiography on long-term outcomes after coronary artery bypass grafting. *Circulation* 2005;112(Suppl. 1):I.293–8.
- [15] Ruel M, Kapila V, Price J, Kulik A, Burwash IG, Mesana TG. Natural history and predictors of outcome in patients with concomitant functional mitral regurgitation at the time of aortic valve replacement. *Circulation* 2006;114(Suppl. 1):I-541–6.
- [16] Heikkinen J, Biancari F, Uusimaa P, Satta J, Juvonen J, Ylitalo K, Niemela M, Salmela E, Juvonen T, Lepojärvi M. Long-term outcome after mitral valve repair. *Scand Cardiovasc J* 2005;39:229–36.
- [17] Perier P, Stumpf J, Götz C, Lakew F, Schneider A, Clausnizer B. Valve repair for mitral regurgitation caused by isolated prolapse of the posterior leaflet. *Ann Thorac Surg* 1997;64:445–50.
- [18] Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. *Circulation* 2003;107:1609–13.
- [19] Barber JE, Kasper FK, Ratliff NB. Mechanical properties of myxomatous mitral valves. *J Thorac Cardiovasc Surg* 2001;122:955–62.
- [20] Fasol R, Mahdjoobian K. Repair of mitral valve billowing and prolapse (Barlow): the surgical technique. *Ann Thorac Surg* 2002;74:602–5.
- [21] Komoda T, Hubler M, Siniawski H, Hetzer R. Annular stabilization in mitral repair without a prosthetic ring. *J Heart Valve Dis* 2000;9:776–82.
- [22] Wilcken DE. Genes, gender and geometry and the prolapsing mitral valve. *Aust N Z J Med* 1992;22:556–61.
- [23] Butchart EG. The significance of sudden and unwitnessed death after heart valve replacement. *J Heart Valve Dis* 1994;2:1–4.